Experienced in Non-Muscle Invasive Bladder Cancer

Dr. Ki Y. Chung

Oncology | Hematology Oncology

Prisma Health

Prisma Health Cancer Institute – Spartanburg

2400 Boiling Springs Road,

Boiling Springs, SC

On Staff At

Clinical Trials:Currently Recruiting for 4 Trials

Accepting New Patients

Offers Telehealth

Experienced in Non-Muscle Invasive Bladder Cancer

Prisma Health

Prisma Health Cancer Institute – Spartanburg

2400 Boiling Springs Road,

Boiling Springs, SC

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ki Chung is a Hematologist Oncology specialist and an Oncologist in Boiling Springs, South Carolina. Dr. Chung is rated as an Experienced provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lung Cancer, and Bone Tumor. Dr. Chung is currently accepting new patients.

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 76 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of North Carolina At Chapel Hill

Residency

Sinai Hospital-Baltimore

Specialties

Oncology

Hematology Oncology

Licenses

Internal Medicine in SC

Board Certifications

American Board Of Internal Medicine

Fellowships

Memorial Sloan-Kettering Cancer Center

Hospital Affiliations

Prisma Health Greer Memorial Hospital

Prisma Health Greenville Memorial Hospital

Prisma Health Patewood Hospital

Spartanburg Medical Center

Prisma Health Hillcrest Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina

HMO
MANAGED MEDICAID PLAN
MEDICARE-MEDICAID PLAN

Aetna

Anthem BCBS

Blue Cross Blue Shield

Blue Shield of California

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Capital Blue Cross

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
OTHER MEDICARE PART D
PPO

CareFirst

Cigna

EmblemHealth

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL
OTHER MEDICARE PART D

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Humana

HMO
INDEMNITY
POS
PPO

Independent Health

Managed Medicaid

OTHER MANAGED MEDICAID

Medicaid

OTHER MEDICAID
STATE MEDICAID

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 11 Less Insurance Carriers -

Locations

Prisma Health Cancer Institute – Spartanburg
2400 Boiling Springs Road, Boiling Springs, SC 29316

Call: 864-599-0731

Other Locations

Prisma Health Cancer Institute Multidisciplinary Center – Faris Rd.
890 West Faris Road, Suite 320, Greenville, SC 29605

Call: 864-455-1200

Prisma Health Cancer Institute – Greer
340 Medical Parkway, Greer, SC 29650

Call: 864-662-4000

Prisma Health Cancer Institute – Institute for Translational Oncology Research
900 West Faris Road, Greenville, SC 29605

Call: 864-455-3600

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

76 Clinical Trials

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Enrollment Status: Recruiting

Publish Date: January 26, 2026

Intervention Type: Other

Study Phase: Not Applicable

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Enrollment Status: Recruiting

Publish Date: January 13, 2026

Intervention Type: Radiation, Other

Study Phase: Phase 3

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer

Enrollment Status: Recruiting

Publish Date: November 14, 2025

Intervention Type: Drug, Device

Study Drugs: Gemcitabine, Nab-paclitaxel

Study Phase: Phase 3

Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

Enrollment Status: Recruiting

Publish Date: September 09, 2025

Intervention Type: Drug, Procedure

Study Phase: Phase 3

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Biological, Radiation, Other

Study Drugs: Cisplatin, Nivolumab

Study Phase: Phase 3

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Avelumab, Cabozantinib S-malate

Study Phase: Phase 3

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Drug, Biological, Procedure

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate

Study Phase: Phase 2/Phase 3

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C

Study Phase: Phase 3

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Enrollment Status: Suspended

Publish Date: February 05, 2026

Intervention Type: Biological, Drug, Procedure, Other

Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab

Study Phase: Phase 3

CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 05, 2026

Intervention Type: Other, Drug

Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix

Study Phase: Phase 3

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: February 02, 2026

Intervention Type: Drug, Biological, Other

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Drug

Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine

Study Phase: Phase 2/Phase 3

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Capecitabine, Fluorouracil, Mitomycin

Study Phase: Phase 2

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Biological, Drug

Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab

Study Phase: Phase 2

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure

Study Phase: Phase 3

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Other, Procedure

Study Phase: Not Applicable

Implementation and Effectiveness Trial of HN-STAR

Enrollment Status: Active_not_recruiting

Publish Date: January 23, 2026

Intervention Type: Other

Study Phase: Not Applicable

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: January 21, 2026

Intervention Type: Drug, Procedure

Study Drugs: Cytarabine, Daunorubicin, Uproleselan

Study Phase: Phase 2/Phase 3

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

Enrollment Status: Active_not_recruiting

Publish Date: January 15, 2026

Intervention Type: Other, Procedure, Drug

Study Drug: Bupropion Hydrochloride Controlled-Release

Study Phase: Phase 3

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Enrollment Status: Completed

Publish Date: January 12, 2026

Intervention Type: Drug

Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel

Study Phase: Phase 3

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Enrollment Status: Completed

Publish Date: December 30, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab

Study Phase: Phase 3

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Enrollment Status: Active_not_recruiting

Publish Date: December 22, 2025

Intervention Type: Other, Dietary supplement, Drug

Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan

Study Phase: Phase 3

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: December 19, 2025

Intervention Type: Drug

Study Drugs: Tucatinib, Trastuzumab, Fulvestrant

Study Phase: Phase 2

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease

Enrollment Status: Active_not_recruiting

Publish Date: December 18, 2025

Intervention Type: Drug, Other

Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate

Study Phase: Phase 2

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Enrollment Status: Active_not_recruiting

Publish Date: December 05, 2025

Intervention Type: Drug

Study Drug: Sotorasib

Study Phase: Phase 2

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Drug, Biological, Procedure, Other, Radiation

Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine

Study Phase: Phase 3

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan

Study Phase: Phase 3

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Enrollment Status: Active_not_recruiting

Publish Date: December 03, 2025

Intervention Type: Other, Drug, Radiation, Procedure

Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide

Study Phase: Phase 3

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Radiation, Drug

Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab

Study Phase: Phase 2

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed

Study Phase: Phase 3

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Cabozantinib, Ipilimumab, Nivolumab

Study Phase: Phase 3

A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Drug

Study Drugs: Carboplatin, Paclitaxel, Pevonedistat

Study Phase: Phase 2

A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Brentuximab, Ipilimumab, Nivolumab

Study Phase: Phase 1/Phase 2

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Phase: Phase 3

Increasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy

Enrollment Status: Completed

Publish Date: November 03, 2025

Intervention Type: Other

Study Phase: Not Applicable

A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Enrollment Status: Completed

Publish Date: October 30, 2025

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Paclitaxel, Ramucirumab

Study Phase: Phase 2

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

Enrollment Status: Active_not_recruiting

Publish Date: October 29, 2025

Intervention Type: Other, Biological, Drug

Study Drugs: Trastuzumab Emtansine, Tucatinib

Study Phase: Phase 3

A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors

Enrollment Status: Terminated

Publish Date: September 23, 2025

Intervention Type: Drug

Study Phase: Phase 2

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 16, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 3

A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

Enrollment Status: Completed

Publish Date: September 15, 2025

Intervention Type: Drug

Study Phase: Phase 1

A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers

Enrollment Status: Completed

Publish Date: September 15, 2025

Intervention Type: Drug

Study Drugs: HB-201, HB-202

Study Phase: Phase 1/Phase 2

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Other, Behavioral

Study Phase: Phase 3

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Enrollment Status: Completed

Publish Date: August 22, 2025

Intervention Type: Drug

Study Drug: Ramipril

Study Phase: Phase 2

Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)

Enrollment Status: Completed

Publish Date: July 16, 2025

Intervention Type: Other

View 46 Less Clinical Trials

Similar Doctors

Advanced in Non-Muscle Invasive Bladder Cancer

Dr. James T. Mcclain

Hematology Oncology | Hematology | Oncology

Advanced in Non-Muscle Invasive Bladder Cancer

Dr. James T. Mcclain

Hematology Oncology | Hematology | Oncology

Anderson Area Cancer Center

2000 E Greenville Street, Suite 5000,

Anderson, SC

(35.2 miles away)

864-512-1658

Languages Spoken:

English

See accepted insurances

Accepting New Patients

James Mcclain is a Hematologist Oncology specialist and a Hematologist in Anderson, South Carolina. Dr. Mcclain is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Anemia, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Mcclain is currently accepting new patients.

Advanced in Non-Muscle Invasive Bladder Cancer

Dr. Stephen H. Dyar

Hematology Oncology | Hematology | Oncology

Advanced in Non-Muscle Invasive Bladder Cancer

Dr. Stephen H. Dyar

Hematology Oncology | Hematology | Oncology

Bon Secours Medical Group Greenville Specialty Care LLC

1 Saint Francis Dr,

Greenville, SC

(11.5 miles away)

513-853-8520

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Stephen Dyar is a Hematologist Oncology specialist and a Hematologist in Greenville, South Carolina. Dr. Dyar is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, Breast Cancer, and Bone Marrow Aspiration. Dr. Dyar is currently accepting new patients.

Advanced in Non-Muscle Invasive Bladder Cancer

Dr. Alexander L. Tremont

Hematology Oncology | Hematology | Oncology

Advanced in Non-Muscle Invasive Bladder Cancer

Dr. Alexander L. Tremont

Hematology Oncology | Hematology | Oncology

Henderson County Hospital Corporation

805 6th Ave W,

Hendersonville, NC

(30.4 miles away)

828-696-1330

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Alexander Tremont is a Hematologist Oncology specialist and a Hematologist in Hendersonville, North Carolina. Dr. Tremont is rated as an Advanced provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Pleuropulmonary Blastoma, Breast Cancer, Muscle Invasive Bladder Cancer, and Non-Muscle Invasive Bladder Cancer. Dr. Tremont is currently accepting new patients.

VIEW MORE NON-MUSCLE INVASIVE BLADDER CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chung's expertise for a condition

ConditionClose